相关实验视频
Updated: Apr 9, 2026

07:57
Assessing Whole-Body Lipid-Handling Capacity in Mice
Published on: November 24, 2020
4.0K
儿童脂质查使用全国电子医疗记录的流行率
Angela M Thompson-Paul1,2, Emily M Kraus3,4,5, Renee M Porter3
1Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
JAMA network open
|July 23, 2024
概括
只有11.3%的9-21岁的美国年轻人接受了脂质查. 在接受查的人中,30.2%的脂质水平异常,严重肥胖显著增加了这种风险.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 公共卫生 公共卫生
- 临床脂质学 临床脂质学
背景情况:
- 美国儿童 (9-11岁) 和年轻成年人 (17-21岁) 推进行全方位脂质查,但其益处和目前的利用情况尚不清楚.
- 了解美国年轻人中脂质查和脂质水平异常的流行程度对于公共卫生倡议至关重要.
研究的目的:
- 确定美国9至21岁年轻人门诊脂质查的患病率.
- 调查查的美国年轻人中异常脂质测量的患病率,根据患者特征和测试类型分层.
主要方法:
- 一项横截面研究分析了来自IQVIA门诊电子病历数据库 (2018-2021) 的数据.
- 包括3,226,002名年龄在9-21岁的年轻人,他们的身高和体重都被测量.
- 使用既定标准定义了异常的脂质水平;身体质量指数 (BMI) 被分类.
主要成果:
- 只有11.3%的研究青少年接受了脂质查.
- 随着年龄和更高的BMI类别,查频率增加.
- 在接受查的个体中,30.2%的脂质水平异常,随着肥胖症的增加,患病率显著上升 (例如,严重肥胖症的2.53倍).
结论:
- 脂质查在美国年轻人中未得到充分利用.
- 在查的年轻人中,异常的脂质水平很常见,特别是那些患有肥胖症的人.
- 在推的年龄组和高风险青年中实施脂质查是有必要的.
相关概念视频
Methods of Documentation VII: EMR
1.6K
Electronic Medical Records (EMRs) primarily center around electronically documenting patients' health information within a single healthcare organization or practice. They contain essential clinical data related to a patient's medical history, diagnoses, medications, treatment plans, lab results, and other pertinent information relevant to the specific encounter or episode of care. EMRs are designed to streamline documentation and workflow processes within individual healthcare...
1.6K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
786
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
786
Pharmacokinetics in Pediatric Patients: Drug Distribution
489
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
489
Pharmacokinetics in Pediatric Patients: Drug Metabolism
346
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
346
Pharmacokinetics in Pediatric Patients: Drug Excretion
383
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
383

